Articles related to RESEARCH & CLINICAL TRIALS

The FDA granted Breakthrough Therapy designation to DT120, an oral lysergide formulation under investigation for major depressive disorder, based on phase 3 findings suggesting rapid and sustained antidepressant effects, though the treatment remains investigational and unapproved.

A prospective multicenter study of 970 adults with suspected mild traumatic brain injury (TBI) found that a rapid point-of-care blood test measuring GFAP and UCH-L1 achieved 96.5% sensitivity and 96.5% negative predictive value for detecting CT-positive intracranial injury, supporting its potential role in reducing unnecessary head CT imaging.

Atorvastatin reduced major cardiovascular events among adults aged 70 years and older without known cardiovascular disease, diabetes, or dementia, but the benefit did not translate into a statistically significant improvement in disability-free survival over nearly six years of follow-up.

Daily low-dose endoxifen reduced mammographic breast density versus placebo in premenopausal women, with fewer tolerability concerns at 1 mg. Whether this surrogate response translates into lower breast cancer incidence remains unknown.

A systematic review and meta-analysis found that inclisiran significantly reduced LDL cholesterol compared with placebo across diverse hyperlipidemia populations. Long-term cardiovascular outcome data remain limited despite consistent lipid-lowering efficacy and favorable safety findings.

Discontinuing statins in adults 75 years and older without prior cardiovascular disease did not increase mortality or major cardiovascular events over three years in a randomized trial. LDL cholesterol rose substantially after discontinuation, and longer-term effects remain uncertain.